Global Blood Therapeutics, Inc.
GBTDelisted Oct 5, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001629137
Global Blood Therapeutics, Inc. was delisted on Oct 5, 2022; its insiders filed their last Form 4 on Oct 6, 2022; 247 institutions reported holding it in 13F filings for Q3 2022, worth $4.67B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q3 2022
Institutional positions in Global Blood Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
GBT is no longer listed, so this page shows Q3 2022. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 247
- +53 vs. Q2 2022
- Shares held
- 68.6M
- −2.91M (−4.1%) vs. Q2 2022
- Total value
- $4.67B
- +$2.39B (+104.5%) vs. Q2 2022
- New holders
- 114
- 54 more added
- Sold out
- 61
- 58 more reduced
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $68 |
| Q1 2026 | 1 | $68 |
| Q4 2025 | 1 | $68 |
| Q3 2025 | 1 | $68 |
| Q2 2025 | 1 | $68 |
| Q1 2025 | 1 | $68 |
| Q4 2024 | 1 | $68 |
| Q3 2024 | 1 | $68 |
| Q2 2024 | 1 | $68 |
| Q1 2024 | 1 | $68 |
| Q4 2023 | 1 | $68 |
| Q3 2023 | 1 | $68 |
| Q2 2023 | 1 | $68 |
| Q1 2023 | 1 | $68 |
| Q4 2022 | 2 | $42.1K |
| Q3 2022 | 247 | $4.67B |
| Q2 2022 | 195 | $2.29B |
| Q1 2022 | 203 | $2.44B |
| Q4 2021 | 206 | $1.91B |
| Q3 2021 | 187 | $1.55B |
| Q2 2021 | 192 | $2.28B |
| Q1 2021 | 214 | $2.70B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Global Blood Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| State of Wyoming | 0 | $0 | 0.00% | −282−100.0% | Sold out |
| Howe & Rusling Inc | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Westside Investment Management, Inc. | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Sugarloaf Wealth Management, LLC | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −108−100.0% | Sold out |
| Washington Trust Advisors, Inc. | 0 | $0 | 0.00% | −102−100.0% | Sold out |
| Elequin Capital LP | 0 | $0 | 0.00% | −61−100.0% | Sold out |
| Bellevue Asset Management, LLC | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| Taylor Wealth Management Partners | – | – | – | – | Not filed |